Inovio maintains that INO-3107 meets accelerated approval criteria by providing a meaningful therapeutic benefit over ...
Inovio Pharmaceuticals (INO) had a slight setback with its timeline on when it could actually file its Biologics License Application [BLA] of INO-3107 for the treatment of patients with recurrent ...
I believe Inovio Pharmaceuticals’ upside rests almost entirely on INO-3107. The FDA set a standard-review PDUFA for October 30, 2026. INO-3107 targets HPV-6/11 RRP, aiming to reduce repeat surgeries ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results